Liposomal Curcumin Inhibits Tumor Growth and Angiogenesis in Lewis Lung Cancer

WANG Li-qiang, SHI Hua-shan, WANG Yong-sheng

Abstract

To prepare water soluble curcumin liposome and investigate its anti-tumour and anti-angiogenic effects. Methods Liposomal curcumin was prepared by alcohol injection method. Proliferation inhibition to murin Lewis lung cancer cell line LL/2 of curcumin liposome was evaluated by MTT assay. Apoptosis and cell cycle arrest induced by liposomal curcumin were analysed by flow cytometry. Anti-tumour effects were investigated in a murine lung cancer model, and the anti-angiogenic effect was determined by aginate encapsulation assay. Results In vitro, liposomal curcumin inhibits the proliferation of LL/2 cells and induces apoptosis and cell cycle arrest. In vivo, the systemic administration of liposomal curcumin resulted in the inhibition of tumour. Aginate encapsulation assay revealed angiogenesis was decreased by curcumin liposome. Conclusion The curcumin liposome treatment can significantly inhibit tumour growth in vivo.

 

Keywords: Liposomal curcumin, Tumour, Angiogenesis

 

Full Text:

PDF


References


Hoefield RA, Kalra PA, Baker PG, et al. The use of eGFR and ACR to predict decline in renal function in people with diabetes. Nephrol Dial Transplant ,2011;26(3) ;887-892.

National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease; evaluation classification, and stratification. Am J Kidney Dis, 2002; 39 (2 Suppl 1); Sl- S266.

Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol,2000; 11(Suppl 15);A0828.

Levey AS, Stevens LA, Schmid CH. Et al. A new equation to estimate glomerular filtration rate. Ann Intern Med.2009; 150 (9):604-612.

Christine W, Ayub A, Naser H, et al. Chronic kidney disease stage in renal transplantation-classification using cystatin С and creatinine equations. Nephrol Dial Transplant. 2007; 22 ( 10) : 3013-3020.

Ahmed Z. Mabood Q. Ahmed S. Comparison between creatinine and cystatin С-based GFR equations in renal transplantation. Nephrol Dial Transplant, 2007; 22 ( 9) : 2659- 2668.

Dharnidharka VR. К won C. Stevens G. Serum cystatin С is superior to creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis,2002;40(2);221-226.

Laterza OF. Price CP. Scott MG. Cystatin C; an improved estimator of glomerular filtration rate, Clin С hem, 2002; 48 (5) :699-707.

Meguro S. Shigihara T. Kabeya Y. et al. Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects. Intern Med.2009;48(9): 657-663.

Maheshwari RK, Singh AK, Gaddipati J. et al. Multiple biological activities of curcumin:a short review. Life Sci.2006; 78 (18);2081-2087.

Li L. Ahmed B. Mehta K. et al. Liposomal curcumin with and without oxaliplatin; effects on cell growth, apoptosis. and angiogenesis in colorectal cancer. Mol Cancer Ther,2007;6 (4):1276-1282.

Thangapazham RL, Puri A, Tele S, et al. Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. Int J Oncol.2008;32(5): 1119-1123.

Mach CM. Mathew L. Mosley SA. et al. Determination of minimum effective dose and optimal dosing schedule for liposomal curcumin in a xenograft human pancreatic cancer model. Anticancer Res, 2009 ; 29С 6): 1895-1899.

Sreekanth CN, Bava SV. Sreekumar E, et al. Molecular evidences for the chemosensitizing efficacy of liposomal curcumin in paclitaxel chemotherapy in mouse models of cervical cancer. Oncogene,2011;30(28);3139-3152.

Cheng AL. Hsu CH. Lin JK. et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21 (4B): 2895- 2900.

Dhillon N. Aggarwal BB. Newman RA, et al. Phase trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res,2008;14( 14):4491 -4499.

Takahashi M. Uechi S. Takara K. et al. Evaluation of an oral carrier system in rats: bioavailability and antioxidant properties of liposome-encapsulated curcumin. J Agric Food Chem.2009; 57(19):9141-9146.

Allen TM. Cullis PR. Drug delivery systems; entering the mainstream. Science,2004 ; 303(5665); 1818-1822.

Hoffmann J, Schirner M. Menrad A. et al. A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res, 1997 ;7( 17): 3847-3851.

Yadav VR, Aggarwal BB. Curcumin: a component of the golden spice, targets multiple angiogenic pathways. Cancer Biol Ther,2011; 11 (2): 236-241.

Carmeliet P. Jain RK. Angiogenesis in cancer and other diseases. Nature,2000;407(6801):249-257.

Gasparini G, Longo R, Toi M. et al. Angiogenic inhibitors:a new therapeutic strategy in oncology. Nat Clin Pract Oncol, 2005;2(11);562-577.


Refbacks

  • There are currently no refbacks.